Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs
Key facts (as of September 26, 2025) What happened this week (Sept. 23–26) Company snapshot & pipeline Scholar Rock is a late‑stage biotech developing apitegromab, a selective antibody that blocks latent myostatin activation to build/maintain skeletal muscle. Pipeline also includes SRK‑181 (anti‑latent TGF‑β1, oncology; Phase 1) and SRK‑439 (next‑gen anti‑latent myostatin; IND planned for 2H25). Scholar Rock+1 The SMA evidence base: apitegromab’s pivotal data The obesity tie‑in: preserving muscle on GLP‑1s What the CRL really means Expert view: “[We] expect the issue to be resolved in under three months,” said BMO’s Evan Seigerman, framing the CRL as a timetable hiccup rather than a thesis break. Reuters Financial position & runway Street consensus, targets